Intellia Therapeutics Inc (NTLA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.36B
Last updated: Nov 17, 2026 at 11:06 AM ET
Intellia Therapeutics Inc (NTLA) Earnings: Report Dates and Results
Intellia Therapeutics (NTLA) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Intellia Therapeutics reported EPS of -$0.91, below the -$0.82 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NTLA has an expected report date of Feb 24, 2027.
NTLA Earnings Call
The latest NTLA earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 40 quarters below that had an estimate, NTLA beat 19, missed 20 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $7.16M, down 48.0% from $13.78M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.91 | -$0.82 | -$0.89 - -$0.71 | -10.98% | Miss | N/A | 16 | 2 up, 0 down | Nov 5, 2026 | $7.16M |
| Jun 30, 2026 | -$0.80 | -$0.80 | -$0.95 - -$0.63 | 0.00% | In line | N/A | 15 | 10 up, 1 down | Aug 6, 2026 | $7.66M |
| Mar 31, 2026 | -$0.81 | -$0.90 | -$1.10 - -$0.72 | +10.00% | Beat | N/A | 17 | 2 up, 0 down | May 11, 2026 | $15.05M |
| Dec 31, 2025 | -$0.83 | -$0.99 | -$1.10 - -$0.81 | +16.16% | Beat | N/A | 18 | N/A | Feb 26, 2026 | $23.02M |
| Sep 30, 2025 | -$0.92 | -$0.98 | -$1.16 - -$0.64 | +6.12% | Beat | N/A | 18 | 3 up, 6 down | Nov 6, 2025 | $13.78M |
| Jun 30, 2025 | -$0.99 | -$1.03 | -$1.30 - -$0.61 | +3.88% | Beat | N/A | 22 | 1 up, 0 down | Aug 7, 2025 | $14.24M |
| Mar 31, 2025 | -$1.10 | -$1.27 | -$1.49 - -$0.89 | +13.39% | Beat | N/A | 18 | 0 up, 1 down | May 8, 2025 | $16.63M |
| Dec 31, 2024 | -$1.27 | -$1.32 | -$1.61 - -$0.86 | +3.52% | Beat | N/A | 23 | 5 up, 3 down | Feb 27, 2025 | $12.87M |
| Sep 30, 2024 | -$1.34 | -$1.37 | -$1.57 - -$1.06 | +2.19% | Beat | N/A | 25 | 2 up, 0 down | Nov 7, 2024 | $9.11M |
| Jun 30, 2024 | -$1.52 | -$1.20 | -$1.44 - -$0.98 | -26.67% | Miss | N/A | 24 | 0 up, 0 down | Aug 8, 2024 | $6.96M |
| Mar 31, 2024 | -$1.12 | -$1.36 | -$1.58 - -$1.02 | +17.65% | Beat | N/A | 22 | 1 up, 0 down | May 9, 2024 | $28.93M |
| Dec 31, 2023 | -$1.46 | -$1.44 | -$1.65 - -$1.01 | -1.39% | Miss | N/A | 23 | 1 up, 0 down | Feb 22, 2024 | N/A |
| Sep 30, 2023 | -$1.38 | -$1.50 | -$1.78 - -$1.21 | +8.00% | Beat | N/A | 23 | 1 up, 1 down | Nov 9, 2023 | $11.99M |
| Jun 30, 2023 | -$1.40 | -$1.33 | -$1.59 - -$1.15 | -5.26% | Miss | N/A | 24 | 0 up, 0 down | Aug 3, 2023 | $13.59M |
| Mar 31, 2023 | -$1.17 | -$1.38 | -$1.70 - -$1.17 | +15.22% | Beat | N/A | 25 | 0 up, 0 down | May 4, 2023 | $12.61M |
| Dec 31, 2022 | -$1.40 | -$1.39 | -$1.70 - -$0.83 | -0.72% | Miss | N/A | 25 | 1 up, 0 down | Feb 23, 2023 | $13.57M |
| Sep 30, 2022 | -$1.49 | -$1.25 | -$1.56 - -$0.28 | -19.20% | Miss | N/A | 26 | 1 up, 0 down | Nov 3, 2022 | $13.27M |
| Jun 30, 2022 | -$1.33 | -$1.30 | -$2.07 - -$0.98 | -2.31% | Miss | N/A | 21 | 0 up, 0 down | Aug 4, 2022 | $14.03M |
| Mar 31, 2022 | -$1.96 | -$1.11 | -$1.90 - -$0.73 | -76.58% | Miss | N/A | 21 | 0 up, 0 down | May 5, 2022 | $11.25M |
| Dec 31, 2021 | -$1.09 | -$0.94 | -$1.12 - -$0.64 | -15.96% | Miss | N/A | 20 | 1 up, 0 down | Feb 24, 2022 | $12.85M |
| Sep 30, 2021 | -$0.97 | -$0.85 | -$1.20 - -$0.59 | -14.12% | Miss | N/A | 14 | 1 up, 0 down | Nov 4, 2021 | $7.20M |
| Jun 30, 2021 | -$1.01 | -$0.61 | -$0.81 - -$0.13 | -65.57% | Miss | N/A | 15 | N/A | Aug 5, 2021 | $6.55M |
| Mar 31, 2021 | -$0.69 | -$0.66 | -$0.75 - -$0.54 | -4.55% | Miss | N/A | 14 | N/A | May 6, 2021 | $6.45M |
| Dec 31, 2020 | -$0.69 | -$0.61 | -$0.77 - -$0.38 | -13.11% | Miss | N/A | 12 | N/A | Feb 25, 2021 | $6.59M |
| Sep 30, 2020 | -$0.47 | -$0.57 | -$0.88 - -$0.26 | +17.54% | Beat | N/A | 12 | N/A | Nov 5, 2020 | $22.22M |
| Jun 30, 2020 | -$0.61 | -$0.67 | -$0.84 - -$0.43 | +8.96% | Beat | N/A | 9 | N/A | Aug 6, 2020 | $16.26M |
| Mar 31, 2020 | -$0.63 | -$0.42 | -$0.87 - $0.31 | -50.00% | Miss | N/A | 10 | N/A | May 7, 2020 | $12.92M |
| Dec 31, 2019 | -$0.57 | -$0.56 | -$0.72 - -$0.47 | -1.79% | Miss | N/A | 10 | N/A | Feb 27, 2020 | $10.94M |
| Sep 30, 2019 | -$0.49 | -$0.61 | -$0.72 - -$0.56 | +19.67% | Beat | N/A | 10 | N/A | Oct 31, 2019 | $10.62M |
| Jun 30, 2019 | -$0.56 | -$0.59 | -$0.79 - -$0.47 | +5.08% | Beat | N/A | 10 | N/A | Aug 1, 2019 | $11.12M |
| Mar 31, 2019 | -$0.49 | -$0.57 | -$0.78 - -$0.48 | +14.04% | Beat | N/A | 7 | N/A | May 2, 2019 | $10.43M |
| Dec 31, 2018 | -$0.43 | -$0.56 | -$0.65 - -$0.34 | +23.21% | Beat | N/A | 8 | N/A | Feb 27, 2019 | $7.88M |
| Sep 30, 2018 | -$0.53 | -$0.49 | -$0.63 - -$0.15 | -8.16% | Miss | N/A | 7 | N/A | Oct 31, 2018 | $7.41M |
| Jun 30, 2018 | -$0.52 | -$0.56 | -$0.59 - -$0.50 | +7.14% | Beat | N/A | 6 | N/A | Aug 1, 2018 | $7.68M |
| Mar 31, 2018 | -$0.51 | -$0.56 | -$0.67 - -$0.44 | +8.93% | Beat | N/A | 6 | N/A | May 1, 2018 | $7.47M |
| Dec 31, 2017 | -$0.61 | -$0.42 | -$0.50 - -$0.28 | -45.24% | Miss | N/A | 5 | N/A | Mar 14, 2018 | $6.67M |
| Sep 30, 2017 | -$0.44 | -$0.49 | -$0.54 - -$0.43 | +10.20% | Beat | N/A | 5 | N/A | Oct 31, 2017 | $7.32M |
| Jun 30, 2017 | -$0.45 | -$0.42 | -$0.45 - -$0.39 | -7.14% | Miss | N/A | 4 | N/A | Aug 1, 2017 | $5.92M |
| Mar 31, 2017 | -$0.36 | -$0.35 | N/A | -2.86% | Miss | N/A | N/A | N/A | May 2, 2017 | $6.21M |
| Dec 31, 2016 | -$0.31 | -$0.22 | N/A | -40.91% | Miss | N/A | N/A | N/A | Mar 14, 2017 | $5.63M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.84, after -$5.25 the year before. It was -$10.61 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.84 | N/A |
| Dec 31, 2024 | -$5.25 | N/A |
| Dec 31, 2023 | -$5.41 | N/A |
| Dec 31, 2022 | -$6.18 | N/A |
| Dec 31, 2021 | -$3.76 | N/A |
| Dec 31, 2020 | -$2.40 | N/A |
| Dec 31, 2019 | -$2.11 | N/A |
| Dec 31, 2018 | -$1.99 | N/A |
| Dec 31, 2017 | -$1.86 | N/A |
| Dec 31, 2016 | -$10.61 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 5,700 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 5,712 | 15 | |
| 2025Q4 | Dec 31, 2025 | 8,426 | 20 | |
| 2025Q3 | Sep 30, 2025 | 4,538 | 19 | |
| 2025Q2 | Jun 30, 2025 | 7,011 | 17 | |
| 2025Q1 | Mar 31, 2025 | 5,129 | 19 | |
| 2024Q4 | Dec 31, 2024 | 6,036 | 15 | |
| 2024Q3 | Sep 30, 2024 | 6,772 | 15 | |
| 2024Q2 | Jun 30, 2024 | 7,844 | 20 |
2026Q2 Earnings Call
Opening remarks
Jason Fredette Vice President, Investor Relations and Corporate Communications Thank you, operator, and hello, everyone. Earlier this morning, we issued a press release outlining recent business updates in our second quarter financial results. This document can be found on the Investors and Media section of Intellia's website at intelliatx.com. At this time, I would like to take a minute to remind listeners that during this call, Intellia management may make certain forward-looking statements. We ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intellia undertakes no duty to update this information unless required by law. Joining me on the call are John Leonard, our Chief Executive Officer; and Ed Dulac, our Chief Financial Officer. With that, I'll now turn the call over to John to begin our business discussion.
John Leonard Chief Executive Officer Thank you, Jason, and good morning, everyone. We're excited to be speaking with you to recap the tremendous progress we made in our Phase III development programs of lonvo-z in hereditary angioedema or HAE, and nex-z in transthyretin amyloidosis or ATTR. The full results of our Phase III HAELO trial in HAE position us very well for a potential approval and launch of the world's first in vivo gene editing product in the first half of next year. We also have gained important new genomic insights that further our understanding of nex-z's profile and could help position us even more favorably within a large and dynamic ATTR market. Let's begin with lonvo-z. Simply put, the second quarter was a momentous period for this program. In April, we reported positive top line results from HAELO and got our rolling BLA submission underway with the FDA. This was followed by our late-breaking oral presentation at EAACI and a concurrent publication in the New England Journal of Medicine, Intellia's sixth manuscript in this prestigious journal. HAELO was an unequivocal success as we achieved statistical significance for the primary and all key secondary endpoints. More specifically, during the 6-month primary observation period, we reported an 87% reduction in mean monthly attacks for lonvo-z versus placebo. 62% of patients were entirely attack-free and therapy-free in the lonvo-z arm. A 23-point improvement was observed for the lonvo-z arm in the total angioedema quality of life score from baseline. For context, a change of just 6 points is considered to be clinically meaningful. The New England Journal manuscript also contained compelling figures and analyses underscoring the unique value proposition that could be afforded by this onetime therapy if it's approved. For instance, patient-level data demonstrated that all patients in the lonvo-z arm experienced attack rate reductions from baseline for weeks 5 to 28.
Frequently Asked Questions About NTLA
When is Intellia Therapeutics's next earnings date?
Intellia Therapeutics's next earnings report is expected for Feb 24, 2027.
Did NTLA beat earnings estimates last quarter?
No. Intellia Therapeutics reported EPS of -$0.91 for the quarter ended Sep 30, 2026, below the -$0.82 estimate by 10.98%.
What EPS do analysts expect from NTLA next quarter?
The consensus EPS estimate for Intellia Therapeutics for the quarter ending Dec 31, 2026 is -$0.78 from 19 analysts, with estimates from -$0.88 to -$0.43.
How often does NTLA beat earnings estimates?
Intellia Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +5.26%.
NTLA pages: Overview, Earnings, Forecast, Financials, Competitors